Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
First Claim
Patent Images
1. A sustained release drug delivery system comprising:
- an inner drug core comprising a therapeutically effective amount of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect;
an inner tube impermeable to the passage of said agent, said inner tube having first and second ends and covering at least a portion of said inner drug core, said inner tube sized and formed of a material so that said inner tube is dimensionally stable to accept said drug core without changing shape;
an impermeable member positioned at said inner tube first end, said impermeable member preventing passage of said agent out of said drug core through said inner tube first end; and
a permeable member positioned at said inner tube second end, said permeable member allowing diffusion of said agent out of said drug core through said inner tube second end.
11 Assignments
0 Petitions
Accused Products
Abstract
A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.
-
Citations
40 Claims
-
1. A sustained release drug delivery system comprising:
-
an inner drug core comprising a therapeutically effective amount of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect;
an inner tube impermeable to the passage of said agent, said inner tube having first and second ends and covering at least a portion of said inner drug core, said inner tube sized and formed of a material so that said inner tube is dimensionally stable to accept said drug core without changing shape;
an impermeable member positioned at said inner tube first end, said impermeable member preventing passage of said agent out of said drug core through said inner tube first end; and
a permeable member positioned at said inner tube second end, said permeable member allowing diffusion of said agent out of said drug core through said inner tube second end. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
administering the sustained release drug delivery system in accordance with claim 1 to a mammalian organism in need of such treatment.
-
-
19. A method for treating a mammalian organism for ocular edema, ocular neovascularization, ocular edema, or ocular inflamation, comprising:
administering a sustained release drug delivery system in accordance with claim 1 to a mammalian organism in need of such treatment, said drug delivery system drug core comprising a therapeutically effective amount of a steroid effective to obtain a desired local or systemic physiological or pharmacological effect.
-
20. A method in accordance with claim 19, wherein said steroid is corticosteroid.
-
21. A method in accordance with claim 20, wherein said corticosteroid is fluocinolone acetonide.
-
22. A method for providing controlled and sustained administration of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect comprising:
inserting a sustained release drug delivery system in accordance with claim 1 at a desired location.
-
23. A method in accordance with claim 22, wherein said inserting step comprises injecting said system at a desired location.
-
24. A method in accordance with claim 22, wherein said inserting step comprises surgically implanting said system at a desired location.
-
25. A method in accordance with claim 22, wherein said inserting step comprises inserting said system in a location selected from the group consisting of the vitreous of the eye, under the retina, and onto the sclera.
-
26. A method in accordance with claim 22, wherein said effective agent is a corticosteroid.
-
27. A method in accordance with claim 26, wherein said corticosteroid is fluocinolone acetonide.
-
28. A method in accordance with claim 22, wherein said effective agent is a neuroprotectant.
-
29. A method in accordance with claim 28, wherein said neuroprotectant is nimodipine.
-
30. A method of manufacturing a sustained drug delivery system, comprising the steps of:
-
positioning a drug core in a tube, said drug core containing a therapeutically effective amount of an active agent; and
positioning an end member to said tube to form a closed-end tube, said end member selected from the group consisting of an impermeable cap and a permeable plug. - View Dependent Claims (31, 32, 33, 34, 35, 36, 37, 38, 39, 40)
forming a port in said impermeable outer layer immediately adjacent to said permeable plug.
-
-
38. A method in accordance with claim 37, wherein said step of forming a port further comprises forming a port immediately adjacent to an end surface of said plug opposite said drug core.
-
39. A method in accordance with claim 37, wherein said step of forming a port further comprises forming a port immediately adjacent to a radial surface of said plug.
-
40. A method in accordance with claim 37, wherein said step of forming a port further comprises forming a plurality of ports.
Specification